volume 93, issue 0, P3-O-089 2020
DOI: 10.1254/jpssuppl.93.0_3-o-089
View full text
|
|
Share

Abstract: Androgen deprivation (castration) therapy andwith anti-androgens have become standardremain the clinical mainstay of treatments for metastatic and aggressive prostate cancer (PCa). Yet, these therapies are limited by the inevitable onset ofmost PCa patients will progress to castration-resistant PCa (CRPC) for several reasons such as the overexpression of androgen receptors (AR). Thus, it is necessary to develop Novel therapies are desired for the advanced PCa. Ca 2+-activated K + channels (K Ca) are key molecu…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals